Simple retinal detachments: Identifying the at-risk case

Eye

Volumn 16, Issue 4, 2002, Pages 404-410

  Asaria, R H Y ^a   Gregor, Z J ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

Adjuvant therapy; Proliferative vitreoretinopathy; Retinal detachment; Risk factors; Treatment

Indexed keywords

COLCHICINE; DAUNORUBICIN; DEXAMETHASONE; FLUOROURACIL; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PACLITAXEL; PLACEBO; RETINOIC ACID; SILICONE OIL;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; EYE TOXICITY; HUMAN; HUMAN TISSUE; INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PREOPERATIVE PERIOD; RABBIT; RETINA DETACHMENT; RETINA MACULA LUTEA; RETINA SURGERY; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; VITREORETINOPATHY; VITREOUS BODY DETACHMENT; WOUND HEALING;

EID: 0036327039     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.eye.6700189     Document Type: Article

References (65)

1. Changing concepts of failures after retinal detachment surgery
2. The classification of retinal detachment with proliferative vitreoretinopathy
3. Cytokines in vitreous humor: Interleukin-6 is elevated in proliferative vitreoretinopathy
4. Cytokines in proliferative vitreoretinopathy
5. Interleukin-1-beta changes the expression of metalloproteinases in the vitreous humor and induces membrane formation in eyes containing preexisting retinal holes
6. The treatment of detached retina by searing the retinal tears
7. The effect of oral 13-cis-retinoic acid on retinal redetachment after surgical repair in eyes with proliferative vitreoretinopathy
8. Evaluation of toxicity and efficacy of a combination of antineoplastic agents in the prevention of PVR
9. Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages
10. Daunomycin and silicone oil for the treatment of proliferative vitreoretinopathy
11. Taxol treatment of experimental proliferative vitreoretinopathy
12. 5-fluorouracil: New applications in complicated retinal detachment for an established antimetabolite
13. Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy
14. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: Results from a randomized, double-blind, controlled clinical trial
15. Noveau Traite des Jeux
16. Massive preretinal retraction. A biomicroscopic study
17. Failure in retinal detachment surgery
18. Clinical factors predisposing to massive proliferative vireoretinopathy in rhegmatogenous retinal detachment
19. The development of severe proliferative vitreoretinopathy after retinal detachment surgery. Grade B: A determining risk factor
20. Severe proliferative vitreoretinopathy and retinal detachment. II. Surgical results with scleral buckling
21. Effect of silicone oil on experimental traction retinal detachment
22. Perisilicone proliferation after vitrectomy for proliferative vitreoretinopathy
23. Results of silicone oil removal in advanced proliferative vitreoretinopathy
24. Clinical risk factors for proliferative vitreoretinopathy
25. Retinal break type and proliferative vitreoretinopathy in nontraumatic retinal detachment
26. Prognostic value of new retinal tears associated with the development of postoperative proliferative vitreoretinopathy
27. A case-control study of risk factors for proliferative vitreoretinopathy in aphakia
28. Comparative study of clinical factors that predispose patients to proliferative vitreoretinopathy in aphakia
29. Expression of vitreous cytokines in proliferative vitreoretinopathy: A prospective study
30. A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy
31. Cytokines in human intraocular inflammation
32. Intercellular adhesion molecule-1 in proliferative vitreoretinopathy
33. Vascular adhesion molecules in vitreous from eyes with proliferative diabetic retinopathy
34. Risk factors for proliferative vitreoretinopathy after primary vitrectomy: A prospective study
35. Comparative study of clinical factors predisposing patients to proliferative vitreoretinopathy
36. Blood-retinal barrier in eyes with long-standing aphakia with apparently normal fundi
37. Blood retinal barriers in eyes with long-standing aphakic eyes after extra- and intracapsular lens extraction
38. Outward transport of fluorescein from the vitreous in aphakic eyes
39. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye
40. How to predict proliferative vitreoretinopathy: A prospective study
41. Detachment of retina
42. The scleral buckling procedures. VII. Silicone implants in reoperations
43. Extraocular repeat surgery of retinal detachment. A minimal approach
44. Cryotherapy during surgery for giant retinal tears and intravitreal dispersion of viable retinal pigment epithelial cells
45. Pneumatic retinopexy. A multicenter randomized controlled clinical trial comparing pneumatic retinopexy with scleral buckling
46. New retinal detachment after pneumatic retinopexy
47. Primary vitrectomy without scleral buckling for rhegmatogenous retinal detachment
48. Who should manage primary retinal detachments?
49. Proliferative vitreoretinopathy: Pathobiology, surgical management, and adjunctive treatment
50. Retinoic acid promotes density-dependent growth arrest in human retinal pigment epithelial cells
51. Effects of vitamin A on retinal pigment epithelial cells in vitro
52. Glucocorticosteroid inhibition of intraocular proliferation after injury
53. Inhibition of intraocular proliferations with intravitreal corticosteroids
54. Oral colchicine for the treatment of experimental traction retinal detachment
55. Taxol for the treatment of proliferative vitreoretinopathy
56. Intraocular daunorubicin for the treatment and, prophylaxis of traumatic proliferative vitreoretinopathy
57. Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy
58. Ocular toxicity of fluorouracil after vitrectomy
59. Fluorouracil for the treatment of massive periretinal proliferation
60. Prolonged localized tissue effects from 5-minute exposures to fluorouracil and mitomycin C
61. Effects of single exposures to antiproliferative agents on ocular fibroblast-mediated collagen contraction
62. Inhibition of intraocular fibrin formation following infusion of low-molecular-weight heparin during vitrectomy
63. A prospective, randomized, clinical trial of heparin therapy for postoperative intraocular fibrin
64. An overview of potential applications of heparin in vitreoretinal surgery
65. Cellular migration, proliferation, and contraction. An in vitro approach to a clinical problem-proliferative vitreoretinopathy